Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01849952 · ClinicalTrials.gov registry record
Evaluating the Expression Levels of MicroRNA-10b in Patients With Gliomas
A clinical trial, sponsored by Dartmouth-Hitchcock Medical Center.
- Terminated
- Registry status
- 94
- Enrollment target
NCT01849952 is a clinical trial that was terminated before completion, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 94 participants.
The verdict
NCT01849952 was terminated before completion, sponsored by Dartmouth-Hitchcock Medical Center.
- TERMINATED
- Registry status
- 94 participants
- Enrollment target
Study Summary
MicroRNAs (miRNA) are molecular biomarkers that post-transcriptionally control target genes. Deregulated miRNA expression has been observed in diverse cancers. In high grade gliomas, known as glioblastomas, the investigators have identified an oncogenic miRNA, miRNA-10b (mir-10b) that is expressed at higher levels in glioblastomas than in normal brain tissue. This study tests the hypothesis that in primary glioma samples mir-10b expression patterns will serve as a prognostic and diagnostic marker. This study will also characterize the phenotypic and genotypic diversity of glioma subclasses. Furthermore, considering the critical function of anti-mir-10b in blocking established glioblastoma growth, the investigators will test in vitro the sensitivity of individual primary tumors to anti-mir-10b treatment. Tumor, blood and cerebrospinal fluid samples will be obtained from patients diagnosed with gliomas over a period of two years. These samples will be examined for mir-10b expression levels. Patient survival, as well as tumor grade and genotypic variations will be correlated to mir-10b expression levels.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2013-10-09 |
| Est. Completion | 2025-08-25 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01849952
The ClinicalTrials.gov registry entry for NCT01849952 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 94 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dartmouth-Hitchcock Medical Center, which has 427 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01849952 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01849952 about?
NCT01849952 is a clinical study titled "Evaluating the Expression Levels of MicroRNA-10b in Patients With Gliomas". MicroRNAs (miRNA) are molecular biomarkers that post-transcriptionally control target genes. Deregulated miRNA expression has been observed in diverse cancers. In high grade gliomas, known as glioblastomas, the investigators have identified an oncogenic miRNA, miRNA-10b (mir-10b) that is expressed a...
What is the current status of trial NCT01849952?
This trial is currently terminated. The enrollment target is 94 participants. The study started on 2013-10-09. Estimated completion is 2025-08-25.
Who is sponsoring clinical trial NCT01849952?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.